Summary
Sixty-two patients with metastatic soft tissue sarcomas of various histological types were treated with Cyvadic. No chemotherapy had been given previously. Complete remission (CR) was obtained in 10 % and complete plus partial remissions (PR) in 20 % of the patients. Mean duration of CR was 25 months, that of PR 2.5 months. Median survival time of r esponders was 28 months, that of nonresponders 14 months. Chemotherapy with a combination of ifosfamide plus cisplatin given to patients with primary or secondary resistance to Cyvadic led to CR + PR in 50 % of the patients.
Zusammenfassung
62, chemotherapeutisch nicht vorbehandelte Patienten mit metastasierten Weichteilsarkomen wurden mit dem Cyvadic-Schema behandelt. Komplette Remissionen wurden bei 10 %, komplette plus partielle Remissionen bei 20 % der Patienten erreicht. Die mittlere Dauer der kompletten Remission betrug 25, der partiellen Remission 2,5 Monate. Die mittlere Überlebenszeit der Patienten, die auf die Therapie ansprachen, lag bei 28 Monaten, bei den nicht-ansprechenden Patienten bei 14 Monaten. Die Chemotherapie mit Ifosfamid plus Cisplatin führte bei 50 % der Patienten mit primärer oder sekundärer Cyvadic-Resistenz zu Remissionen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literatur
Gottlieb JA, Baker LH, O'Bryan RM, Sinkovics G, Hoogstraten B, Quagliana JM, Rivkin SE, Bodey GP, Rodriguez VT, Blumenschein GR, Saiki JH, Coltman C Jr, Burgess MA, Sullivan P, Thigpen T, Bottomley R, Balcerzak S, Moon TE (1975) Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep 6:271–282
Yap BS, Baker LH, Sinkovics JG, Rivkin SE, Bottomley R, Thigpen T, Burgess MA, Benjamin RS, Bodey GP (1980) Cyclophosphamide, vincristine, adriamycin, and DTIC (Cyvadic) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64:93–98
Blum RH, Corson JM, Wilson RE, Greenberger JS, Canellos GP, Frei E III (1980) Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD). Cancer 46:1722–1726
Bierbaum W, Bremer K, Firusian N, Higi M, Niederle N, Scheulen ME, Schwalbe HP, Schmidt CG, Seeber S (1981) Chemotherapeutische Behandlungsmöglichkeiten bei fortgeschrittenen Sarkomen. Dtsch Med Wochenschr (im Druck)
Becher R, Seeber S, Schmidt CG (1980) Combination chemotherapy with ifosfamide and cisdichlorodiammineplatinum(II) in advanced malignant melanoma. J Cancer Res Clin Oncol 97:301
Ettinger LJ, Douglass HO Jr, Higby DJ, Bjornsson S, Mindell ER, Freeman AI (1978) Adjuvant adriamycin and cisdiammine dichloroplatinum in primary osteogenic sarcoma. Proc Am Ass Cancer Res Am Soc Clin Oncol 19:323, Abstr C-67
Bramwell VHC, Brugarolas A, Mouridsen HT, Cheix F, De Jager R, Van Oosterom AT, Vendrik CP, Pinedo HM, Sylvester R, De Pauw M (1979) E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma. Eur J Cancer 15:1511–1513
Karakousis CP, Holtermann OA, Holyoke ED (1979) Cis-Dichlorodiammineplatinum(II) in metastatic soft tissue sarcomas. Cancer Treat Rep 63:2071–2075
Karakousis CP, Rao U, Carlson M (1980) High-dose methotrexate as secondary chemotherapy in metastatic soft-tissue sarcomas. Cancer 46:1345–1348
Subramanian S, Wiltshaw E (1978) Chemotherapy of sarcoma. A comparison of three regimens. Lancet 1: 683–686
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hossfeld, D.K., Seeber, S., Siemers, E. et al. 20. Chemotherapie der Weichteilsarkome. Langenbecks Arch Chiv 355, 147–151 (1981). https://doi.org/10.1007/BF01286830
Issue Date:
DOI: https://doi.org/10.1007/BF01286830